Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated IGHV, 45% del(17p), and 26.8% complex karyotype (≥ 3 abnormalities). Prior to venetoclax initiation, 89% received a B-cell receptor antagonist. For tumor lysis syndrome prophylaxis, 93% received allopurinol, 92% normal saline, and 45% rasburicase. Dose escalation to the maximum recommended dose of 400 mg daily was achieved in 85% of patients. Adverse events of interest included neutropenia in 47.4%, thrombocytopenia in 36%, tumor lysis syndrome in 13.4%, neutropenic fever in 11.6%, and diarrhea in 7.3%. The overall response rate to venetoclax was 72% (19.4% complete remission). With a median follow up of 7 months, median progression free survival and overall survival for the entire cohort have not been reached. To date, 41 venetoclax treated patients have discontinued therapy and 24 have received a subsequent therapy, most commonly ibrutinib. In the largest clinical experience of venetoclax-treated chronic lymphocytic leukemia patients, the majority successfully completed and maintained a maximum recommended dose. Response rates and duration of response appear comparable to clinical trial data. Venetoclax was active in patients with mutations known to confer ibrutinib resistance. Optimal sequencing of newer chronic lymphocytic leukemia therapies requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Howard, S. C., Jones, D. P., & Pui, C.-H. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0904569 · Cited by 1,044
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713976 · Cited by 940
Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30909-9 · Cited by 383 · cited 3×
“in patients who were treated with venetoclax following ibrutinib.(5) Finally, we did not observe a difference in PFS whether venetoclax was given alone or in combination.”
BackgroundSelf-citation
Cited by
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, A. R., Shah, N. N., Jurczak, W., Cheah, C. Y., Pagel, J. M., Woyach, J. A., Fakhri, B., Eyre, T. A., Lamanna, N., Patel, M. R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00224-5 · Cited by 466
Self-citationMitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.005 · Cited by 361
Metadata
- Authors
- Mato, A. R., Thompson, M., Allan, J. N., Brander, D. M., Pagel, J. M., Ujjani, C. S., Hill, B. T., Lamanna, N., Lansigan, F., Jacobs, R., Shadman, M., Skarbnik, A. P., Pu, J. J., Barr, P. M., Sehgal, A. R., Cheson, B. D., Zent, C. S., Tuncer, H. H., Schuster, S. J., Pickens, P. V., Shah, N. N., Goy, A., Winter, A. M., Garcia, C., Kennard, K., Isaac, K., Dorsey, C., Gashonia, L. M., Singavi, A. K., Roeker, L. E., Zelenetz, A., Williams, A., Howlett, C., Weissbrot, H., Ali, N., Khajavian, S., Sitlinger, A., Tranchito, E., Rhodes, J., Felsenfeld, J., Bailey, N., Patel, B., Burns, T. F., Yacur, M., Malhotra, M., Svoboda, J., Furman, R. R., & Nabhan, C.
- Venue
- Haematologica
- Published
- 2018-06-07
- Volume
- 103
- Issue
- 9
- Pages
- 1511-1517
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2806285688
- Cited by
- 165
- References
- 4
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. https://app.cochat.ai/papers/10.3324/haematol.2018.193615
- The paper
- Mato, A. R., Thompson, M., Allan, J. N., Brander, D. M., Pagel, J. M., Ujjani, C. S., Hill, B. T., Lamanna, N., Lansigan, F., Jacobs, R., Shadman, M., Skarbnik, A. P., Pu, J. J., Barr, P. M., Sehgal, A. R., Cheson, B. D., Zent, C. S., Tuncer, H. H., Schuster, S. J., . . . Nabhan, C. (2018). Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. https://doi.org/10.3324/haematol.2018.193615
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.